NFE2L2 and asthma: Interestingly, we report the discovery that NRF2 activation by KEAP1 knockdown or by pharmacological activators of NRF2 can specifically inhibit Eotaxin-1/CCL11 expression in human lung fibroblasts independent of several other chemokines further implicating this pathway in asthma pathogenesis.